NO2627673T3 - - Google Patents

Info

Publication number
NO2627673T3
NO2627673T3 NO11769881A NO11769881A NO2627673T3 NO 2627673 T3 NO2627673 T3 NO 2627673T3 NO 11769881 A NO11769881 A NO 11769881A NO 11769881 A NO11769881 A NO 11769881A NO 2627673 T3 NO2627673 T3 NO 2627673T3
Authority
NO
Norway
Application number
NO11769881A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2627673T3 publication Critical patent/NO2627673T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/087—Measuring breath flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
NO11769881A 2010-10-15 2011-10-14 NO2627673T3 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39367710P 2010-10-15 2010-10-15
US201161508723P 2011-07-18 2011-07-18
PCT/EP2011/067947 WO2012049278A1 (en) 2010-10-15 2011-10-14 Therapies for improving pulmonary function

Publications (1)

Publication Number Publication Date
NO2627673T3 true NO2627673T3 (enExample) 2017-12-23

Family

ID=44800047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11769881A NO2627673T3 (enExample) 2010-10-15 2011-10-14

Country Status (15)

Country Link
US (1) US20130281876A1 (enExample)
EP (1) EP2627673B1 (enExample)
JP (1) JP2013544235A (enExample)
CN (1) CN103328506A (enExample)
AU (1) AU2011315499A1 (enExample)
BR (1) BR112013009055A2 (enExample)
CA (1) CA2814431A1 (enExample)
DK (1) DK2627673T3 (enExample)
ES (1) ES2645368T3 (enExample)
HU (1) HUE034005T2 (enExample)
MX (1) MX2013004212A (enExample)
NO (1) NO2627673T3 (enExample)
PL (1) PL2627673T3 (enExample)
RU (1) RU2013122123A (enExample)
WO (1) WO2012049278A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
WO2015112970A1 (en) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CN104605857A (zh) * 2015-02-12 2015-05-13 上海朔茂网络科技有限公司 一种肺功能测量方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
JP2025501239A (ja) 2021-12-30 2025-01-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4/il-13アンタゴニストを投与することによってアトピーマーチを減弱する方法
WO2026151705A1 (en) * 2025-01-07 2026-07-16 Apogee Therapeutics, Inc. Dosage and administration of interleukin-13 antibody to treat asthma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
HUE034005T2 (en) 2018-01-29
EP2627673A1 (en) 2013-08-21
BR112013009055A2 (pt) 2016-07-19
EP2627673B1 (en) 2017-07-26
DK2627673T3 (da) 2017-11-06
US20130281876A1 (en) 2013-10-24
CN103328506A (zh) 2013-09-25
MX2013004212A (es) 2013-09-02
RU2013122123A (ru) 2014-11-20
JP2013544235A (ja) 2013-12-12
PL2627673T3 (pl) 2018-01-31
WO2012049278A1 (en) 2012-04-19
ES2645368T3 (es) 2017-12-05
CA2814431A1 (en) 2012-04-19
AU2011315499A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
BR112012019354A2 (enExample)
BR112012030039A2 (enExample)
BR112012028408A2 (enExample)
BR112012024897A2 (enExample)
BR112012031500A2 (enExample)
BR112012025307A2 (enExample)
BR112012002126A2 (enExample)
BR112012025482A2 (enExample)
BR112012031826A2 (enExample)
BR112012025577A2 (enExample)
BR112012023249A2 (enExample)
BR112012028186A2 (enExample)
BR112012027015A2 (enExample)
BR112012025308A2 (enExample)
BR112012027945A2 (enExample)
BR112012026403A2 (enExample)
BR112012024872A2 (enExample)
BR112013003284A2 (enExample)
BR112013002646A2 (enExample)
BR112012022788A2 (enExample)
BR112012016895A2 (enExample)
BR112012028859A2 (enExample)
BR112013007728A2 (enExample)
BR112012029562A2 (enExample)
BR112012027756A2 (enExample)